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NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET 
DET MEDISINSKE FAKULTET 
Intracellulære signalmekanismer i den medfødte immunresponsen til virus 
infeksjoner 
 Infeksjoner forårsaket av aggressive virus, som enkelte varianter av influensa virus og 
coronavirus som forårsaker ”severe acute respiratory syndrome” (SARS), er forbundet med 
høy dødelighet og utgjør en betydelig global trussel. Kroppens første møte med mikrobielle 
patogener er mediert av reseptorer i immuncellene. Disse reseptorene gjenkjenner spesifikke 
patogene komponenter og har fått fellesbetegnelsen ”mønster gjenkjennings reseptorer” 
(PRR). De best studerte PRRene kalles Toll lignende reseptorer (TLR) og er transmembrane 
proteiner som finnes enten på celleoverflaten eller intracellulært. I tillegg har man nylig 
identifisert flere cytoplasmiske reseptorer, delt inn i Nod-lignende reseptorer (NLR) og RIG-
I-lignende reseptorer (RLR). Eksempler på patogene komponenter som gjenkjennes er deler 
av celleveggen til bakterier, som lipopolysakkarid (LPS), og virale nukleinsyrer. 
 De fleste virus entrer cellen via endocytose, fusjonerer med endosomale membraner og 
frigir arvematerialet sitt i cytoplasma. Cellen er utstyrt med et repertoire av 
gjenkjenningsmekanismer på ulike trinn av virus infeksjonen, f.eks. TLR3 som binder viralt 
dobbeltrådet RNA (dsRNA) i endosomet og RIG-I som binder viralt enkeltrådet RNA 
(ssRNA) i cytoplasma.  Etter at TLR3 eller RIG-I har bundet virale nukleinsyrer settes det i 
gang signalmekanismer som involverer ulike adapter proteiner, kinaser og 
transkripsjonsfaktorer. Disse mekanismene regulerer genuttrykket av antivirale cytokiner og 
interferoner (IFN). TLR3- og RIG-I-avhengige responser resulterer i høy aktivering av 
transkripsjonsfaktoren interferon regulerende faktor (IRF) 3 og påfølgende produksjon av 
type I IFN, en viktig faktor i kroppens medfødte forsvar mot virus. Likevel er de molekylære 
mekanismene bak interaksjonen mellom virus og vertscelle fortsatt i stor grad ukjent. I dette 
studiet beskriver vi betydningen av c-Src, en tyrosin kinase, i antiviral signalisering mediert 
av virus-gjenkjennende PRRer. 
 I første del av dette arbeidet viser vi at c-Src aktiveres av viralt dsRNA og assosierer 
med TLR3. Ved hjelp av kjemisk og genetisk hemming fant vi at c-Src er viktig for antiviral 
immunrespons, spesifikt for aktivering av transkripsjonsfaktorene IRF3 og STAT1 i respons 
til dsRNA, og at kinasen utøver sin funksjon nedstrøms for TLR3 adapterproteinet TRIF. Ved 
bruk av konfokal mikroskopi så vi at viralt dsRNA blir tatt opp i cellen via endocytose. Vi 
fant TLR3 i endoplasmatisk retikulum i hvilende celler, og etter tilsats av dsRNA observerte 
vi en fraksjon av TLR3 i endosomale strukturer. Vi observerte også økt lokalisering av c-Src i 
endosom/lysosom i dsRNA-behandlede celler. Videre resultater viser at c-Src også forsterker 
den antivirale responsen til Sendai virus (SV), som gjenkjennes av den cytoplasmiske 
reseptoren RIG-I. Spesifikt viser vi at hemming eller utslåing av c-Src nedsetter SV-indusert 
aktivering av transkripsjonsfaktoren IRF3 og induksjon av IFN-ȕ nedstrøms for RIG-I og 
adapterproteinet MAVS. C-Src assosierer med flere komponenter i RIG-I signalveien, og 
interagerer spesifikt med RING domenet til et cytoplasmisk adapterprotein kalt TRAF3, som 
er viktig for både TLR3- og RIG-I-mediert immunrespons til virus. I siste del av arbeidet så vi 
at utslåing av c-Src hemmer IRF3 aktivering og induksjon av IRF3-regulert genuttrykk (IP10) 
i tidlig TLR-mediert respons. I en senere fase av TLR responsen observerte vi imidlertid at 
manglende c-Src funksjon øker IRF5 aktivering og induksjon av IRF5-regulert genuttrykk 
(IL-6). Vi fant at c-Src positivt regulerer utrykket av transkripsjonsfaktoren ATF3, en negativ 
regulator av TLR-indusert IL-6 produksjon. 
 Samlet viser disse resultatene at c-Src tyrosin kinase medvirker i antivirale 
immunresponser nedstrøms for ulike PRRs og sannsynligvis i respons til flere virus. TLR3 
gjenkjenner viralt dsRNA i endosom/lysosom og rekrutterer c-Src for å sette i gang antiviral 
signalisering. C-Src assosierer med adapterproteinet TRAF3, hvor signalveiene fra TLR3 og 
RIG-I møtes, og binder spesifikt til dets RING domene. C-Src utøver en differensiel rolle i 
medfødt immunaktivering av IRF transkripsjonsfaktorer, og hemmer TLR-trigget IL-6 
induksjon ved å kontrollere ATF3 uttrykket i en sen fase av TLR responser. 
 Vi tror at disse resultatene bidrar til økt forståelse av medfødte responsmekanismer til 
virus infeksjon. Slik forståelse er essensiell for utvikling av nye antivirale behandlingsformer 
og vaksiner. 
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PRR   pattern recognition receptor 
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 1 INTRODUCTION
A virus is an infectious agent that is unable to grow and reproduce outside a host cell.  
Various viruses can infect almost any type of body tissue, from the brain to the skin. In 
contrast to bacterial infections, viral infections cannot be treated with antibiotics. In fact, in 
most cases human viral infections can be effectively fought by the body's own immune 
system. Still emerging viruses, such as the H5N1 variant of the influenza virus and the 
coronavirus causing subacute airway respiratory syndrome (SARS), cause substantial 
morbidity and mortality. Importantly several cancers are associated with viral infections, e.g.
cervical cancer which is closely associated with human papillomavirus (HPV) and liver 
cancer which is caused mainly by chronic hepatitis B or hepatitis C infection. Knowledge of 
host-virus interactions and antiviral immunity is important to provide improved strategies for 
antiviral vaccines, and more effective treatments for viral infectious disease as well as virus-
associated cancer. 
The immune system is a collection of mechanisms within an organism that protects against 
foreign pathogens as well as endogenous malignant cells. The human body possesses both 
innate and adaptive immune defences which comprise distinct mechanisms. The adaptive 
immune system is acquired and has the feature of specific long-lasting memory, but it takes 
time before it reaches its maximum efficiency. Meanwhile an immediate response to invading 
pathogens is required to prevent replication and spread of the infectious agent. This shows the 
importance of the germ-line encoded mechanisms referred to as the innate immune system. 
All these processes rely mainly on specialized cells and molecules inside the body. 
 1.1  Pattern recognition of the innate immune system 
The main function of the innate immune system is to recruit immune cells to sites of infection 
through the induction of cytokines and interferons (IFNs) prior to activation of an adaptive 
immune response. Subsequently foreign substances are identified and removed by specialized 
phagocytic cells, such as neutrophiles, macrophages and dendritic cells (DCs).  To mount an 
appropriate defence against invading pathogens, the phagocytic cells are dependent on germ-
line encoded receptors termed pattern recognition receptors (PRRs). PRRs recognize pathogen 
associated molecular patterns (PAMPs) that distinguish foreign organisms from host cells. 
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Such molecular patterns include viral nucleic acids, parts of the bacterial cell wall, bacterial 
flagellar proteins and more. However, this detection system is not foolproof and may be 
inadversely activated by host molecules secreted during stress or by dying cells (1). Such 
endogenous stress signals are termed damage-associated molecular patterns (DAMPs). 
Inadvertent activation of PRRs by DAMPs may have an important role in autoimmune and 
inflammatory diseases (2).  Upon pattern recognition and activation of PRRs, specific adaptor 
molecules are recruited to the receptor leading to the initiation of distinct signaling cascades 
that regulate the transcription of pro- and anti-inflammatory cytokines necessary for the early 
immune response.
The most studied PRRs are the Toll-like receptors (TLRs). At present 11 different TLRs 
(numbered 1-11) are described in human, all recognizing different molecular patterns and 
initiating specific signaling cascades. The TLRs are found either at the plasma membrane 
where they recognize invading pathogens on the surface of the cell, or in the 
endosomes/lysosomes where they signal viruses entering the cell by endocytosis. However, 
both bacteria and viruses may at some point enter the cytoplasm in which the TLRs are poorly 
represented. Recently several cytoplasmic pattern recognition receptors have been discovered. 
They have been divided into two families, the NLR family (nucleotide-binding 
oligomerization domain (NOD)-like receptor family) and the RLR family (RIG-I like receptor 
family). The NLR family consists of at least 23 members, either NOD receptors generally 
activating NF-țB, or NALPs (NACHT-, LRR-and pyrin-domain containing proteins) known 
to activate caspase-1 to control the processing of the pro-inflammatory cytokines IL-1ȕ and 
IL-18 (3). The RLR family is formed by at least two members named RIG-I and Mda5, both 
important for the recognition of viral RNA. In 2007, the double-stranded DNA-binding 
protein DAI (DNA-dependent activator of IFN-regulatory factors) was identified as a 
candidate cytoplasmic DNA sensor with roles in infections in vivo, but its functions remain to 
be shown (4). Very recently, the PYHIN family member absent in melanoma 2 (AIM2) was 
identified as a receptor for cytosolic DNA which regulates caspase-1 (5). Knock-down of 
Aim2 abrogates caspase-1 activation in response to cytoplasmic dsRNA and dsRNA vaccinia 
virus.
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 1.1.1 Toll-like receptors 
TLRs are evolutionary conserved from the worm Caenorhabditis elegans to mammals (6;7). 
The founding TLR member Toll was originally identified as a protein important for the 
development of embryonic dorsoventral polarity in Drosophila (8). Later it was found to be 
critical for the response against fungal infection in flies (9). Next, a mammalian homolog of 
the Toll receptor was shown to induce expression of genes involved in inflammatory 
responses (10). This homolog was identified as the key receptor for LPS (11) and is today 
known as TLR4.
TLRs are capable of sensing organisms ranging from bacteria to fungi, protozoa, and viruses. 
They are transmembrane signaling receptors that are expressed on cellular membranes; either 
on the plasma membrane or on intracellular vacuolar membranes. Their structure consists of 
extracellular leucin-rich repeats (LLRs), which differ between the TLRs, and a cytoplasmic 
Toll-interleukin-1 receptor (TIR) domain (12). Upon ligand binding the TLRs utilize their 
common TIR domain to transmit intracellular responses through the homologous recruitment 
of TIR-contaning adaptor proteins (6;13). The pattern of the response depends on the 
combination of PAMPs and TLRs. In general, TLR4 recognizes lipopolysaccharide (LPS) 
from Gram-negative bacteria, TLR3 senses viral double-stranded RNA (dsRNA), TLR7 and 
TLR8 senses viral singel-stranded RNA (ssRNA), whereas TLR9 specifically responds to 
bacterial nonmethylated CpG DNA motifs (TLR9) (11;14-18). The TLRs utilize TIR-domain 
containing adaptor proteins to propagate the signal. All TLRs except TLR3 activate 
downstream signaling components through MyD88. TLR3 on the other hand utilizes the 
adaptor protein TRIF (19-22), which is mainly responsible to type-I IFN. TLR4 signals 
through both MyD88 and TRIF. In addition TLR4 use the TRIF-related adaptor molecule 
(TRAM), which functions to recruit and activate TRIF (23). In contrast to TLR4 signaling, 
TLR3 recruits TRIF directly. The intracellular signaling cascades initiated by the TLRs often 
involve protein kinases and ligases. The pathways diverge at the level of the adaptor proteins. 
However, there is complex cross-talk between the distinct pathways. Signals generated from 
MyD88 mainly regulate NF-țB dependent transcription of pro-inflammatory cytokines, 
whereas TRIF-induced pathways generally regulate interferon regulatory factor (IRF) 3 and 
IRF7 dependent transcription of type-I IFNs. However, TLR-stimulated signaling through 
TRIF is also capable of activating NF-țB.
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The Toll-like receptors are localized in different organelles. TLR1, TLR2, TLR4, TLR5 and 
TLR6 recognize the invading pathogen on the surface of the cell and show localization to the 
plasma membrane. TLR3, TLR7, TLR8, and TLR9, on the other hand, localize to the 
endoplasmic reticulum (ER) in resting cells, but a fraction enters the endosomal pathway to 
capture the entering virus and transmit an antiviral signal. The mechanism by which the 
receptors are trafficked to the endosomes/lysosomes is not understood. However, it has been 
reported that a missense mutation in the membrane protein UNC93B1 abrogates translocation 
of TLR7 and TLR9 from the ER to endolysosomes (24). Very recently it was shown that 
proteolytic cleavage of TLR9 is a prerequisite for its signaling (25), demonstrating the 
importance of lysosomal localization. The TLRs localizing to endosomes/lysosomes share the 
ability to recognize viral and bacterial nucleic acids, nevertheless they have the potency to 
respond to endogenous nucleic acids (15;26). Importantly, their localization to intracellular 
vesicles could prevent them from responding to self components (26). 
8
Figure 1: Overview of TLR 1-9, their ligands and the TIR adaptors they utilize for downstream signaling. 
                                                                                                                                                                                       
Bacterial sensing by TLRs 
Bacteria may be classified as Gram-negative and Gram-positive bacteria based on the 
characteristics of their cell wall. Some of the unique cell-wall components are potent PAMPs 
for PRRs in immune cells. LPS from Gram-negative bacteria is the most potent 
immunostimulant among these cell-wall components, in particular due to a lipid portion 
termed lipid A. LPS is the ligand of TLR4, which is highly expressed on the cell surface of 
monocytes (27-29).  LPS interacts with LPS binding protein (LBP) and binds CD14, a protein 
expressed on the surface of phagocyting cells. LPS is then transferred to MD2 which 
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associates with the extracellular domain of TLR4. TLR4 undergoes oligomerization and 
initiates LPS signaling (11;30).
Lipoteichoic acid (LTA), a cell-wall component of Gram-positive bacteria, seems to function 
in a similar manner as LPS as an immune activator. TLR2 is expressed on the cell surface of 
monocytes and myeloid DCs (27-29;31), and is the major detectant of Gram-positive bacteria 
such as Staphylococcus aureus and Mycobacteria. TLR2 is reported to recognize a variety of 
microbial components, including LTA, lipoprotein, peptidoglycan, zymosan and porins. 
TLR2 interacts physically and functionally with TLR1 and TLR6, which may explain its wide 
repertoire of ligands (32-34). TLR2/TLR1 heterodimerization occurs in response to 
triacetylated lipopeptides, whereas TLR2/TLR6 heterodimerization occurs upon stimulation 
with diacetylated lipopeptides and LTA (33-35). 
Flagellin, the motility apparatus of many microbial pathogens, is another potent immune 
stimulator. TLR5, also expressed on the cell surface of monocytes and myeloid DCs (27;28), 
recognizes flagelling and is reported to specifically detect the D1 domain of the flagellin, 
which consists of well conserved central Į-helical chains (36;37). Another bacterial 
immunostimulant is unmethylated CpG-DNA. The CpG motif is abundant in bacterial 
genomes, but not in mammalian DNA. Moreover, mammalian, but not bacterial CpG-DNA, is 
highly methylated (38). TLR9, specifically expressed intracellularly in plasmacytoid DCs 
(pDCs) (27;29), recognizes and interacts directly with CpG-DNA that has been delivered to 
intracellular vesicles (39;40). As previously mentioned, it was demonstrated that the TLR9 
ectodomain is cleaved in the endolysosome, and that the truncated receptor rather than the 
full-lenght form is functional and recruits MyD88 (41). This may represent a strategy to 
restrict receptor activity to the endosomes/lysosomes, thus preventing TLRs from responding 
to self molecules.  
Viral sensing by TLRs 
Viruses contain genetic material, either DNA or RNA, encoding viral structural components, 
such as replication enzymes and proteases. Viral PAMPs recognized by PRRs are mainly 
DNA, ssRNA, dsRNA and surface proteins. Among the TLR family, TLR3, TLR7, TLR8 and 
TLR9 are able to respond to viral infections. DNA viruses that contain genomes rich in 
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unmethylated CpG motifs, such as herpes simplex virus 1 (HSV-1), HSV-2 and mouse 
cytomegalovirus (MCMV) are recognized by TLR9. This activates induction of type I IFNs. 
However, TLR9-mediated IFN-Į production in response to HSV-1 and HSV-2 is cell-type 
specific and occurs only in pDCs. Macrophages also induce type I IFNs upon HSV infection, 
suggesting that cells other than pDCs have TLR9 independent systems for antiviral responses.  
Viral ssRNA is recognized by TLR7 and TLR8. TLR7 signals in response to ssRNA in both 
human and mouse, whereas TLR8 may function only in human (16;42).  The genes encoding 
TLR7 and TLR8 are highly homologous to each other and are both located on the X 
chromosome. However, these two TLRs show differences in cell-type specific expression in 
human. TLR7 is expressed on intracellular vesicles in pDCs, whereas TLR8 is expressed 
intracellularly in monocytes and mDCs (27;29). Both TLR7 and TLR8 mediate response to 
ssRNA derived from human immunodeficency virus (HIV), and to synthetic antiviral 
imidazoquinoline components (R848, Imiquimod). TLR7 is also reported to respond to 
ssRNA from influenza virus, synthetic poly U and small interfering RNAs (15;16;18;43;44).  
DsRNA and a synthetic dsRNA analogue, polyinosinic acid:cytidylic acid (poly IC), are 
recognized by TLR3 (14). DsRNA is synthesized during replication of many viruses, either as 
a replication intermediate of ssRNA viruses (e.g. EMCV and West Nile viruses) or as a by-
product of symmetrical transcription in DNA viruses (e.g. MCMV). In addition, TLR3 is able 
to recognize dsRNA derived from dsRNA viruses such as reovirus (45-47). Besides 
expression in epithelial cells, TLR3 is specifically expressed in natural killer (NK) cells and 
conventional DCs, but not in pDCs (48-52). The 3-dimensional structure of the TLR3 
ectodomain (ECD) has recently been solved. It is a horseshoe-shaped solenoid consisting of 
23 LRRs. TLR3 is masked by carbohydrates, but one side of the ECD is glycosylation-free 
(53;54). Mutational analysis has located the dsRNA binding site within the glycan-free, lateral 
surface towards the C-terminal region of TLR3 (55). TLR3 ectodomains dimerize on 
oligonucleotides of 40-50 base pairs, which is suggested to be the minimum length of the 
dsRNA sequence required for signal transduction (56). In contrast to TLR4, TLR3 binds its 
ligand directly (54).
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Finally, viral envelope glycoproteins are recognized by TLR4 and TLR2. This, however, 
leads to the production of pro-inflammatory cytokines rather than type I IFNs. Thus, detection 
of viral glycoproteins results in inflammation, but not specific antiviral responses (57). 
 1.1.2 RIG-I-like helicases 
RIG-I and Mda5 are members of the DEAD-box RNA helicases. They are both composed of 
two N-terminal caspase recruitment domains (CARDs) and a C-terminal RNA helicase 
domain (58-60). Despite the structural similarities the RIG-I like helicases (RLHs) display 
high degree of specificity on virus detection. Cytokine secretion is markedly reduced in RIG-I 
-/- cells infected with Sendai virus (SV), Newcatle disease virus (NDV), Vesicular stomatitis 
virus (VSV), Influenza A virus and Japanese encephalitis virus (JEV). On the other hand, 
cytokine production in response to EMCV, Thyler`s virus and Mengo virus, all 
Picornaviruses, is almost absent in Mda5 -/- cells (61). Additionally, it is believed that RIG-I 
discriminates between self- and non-self-RNA by specifically binding RNA, both ds and ss, 
containing free 3-phosphate on its 5`-end (62;63). RIG-I and Mda5 utilize the adaptor protein 
MAVS (also called Cardif, VISA and IPS) in a CARD-CARD dependent manner to trigger 
antiviral response (64-67). MAVS is anchored to the mitochondrial outer membrane through a 
short part of its C-terminal, and recruits signaling molecules crucial for the activation of NF-
țB and IRF7 and/or IRF3, and subsequent induction of type-I IFNs. It has been suggested, as 
for the TLRs, that RIG-I and Mda5 signaling pathways diverge on the level of the adaptor 
protein.
Figure 2: Domain structure of RIG-I and MAVS. RIG-I contains two N-terminal CARD domains and a C-
terminal DEAD-box/helicase domain. MAVS contains one N-terminal CARD-domain in addition to a proline-
rich region and a C-terminal transmembrane region.  
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 1.1.3 NOD-like receptors 
The NOD like receptors (NLRs) comprise two subclasses, the NODs (numbered 1-5) and the 
14 members of the NALPs, giving a total number of 22 NLRs identified so far (68). NLRs 
contain three domains: an N-terminal CARD or pyrin effector domain, a nucleotide-binding 
and oligomerization domain called NACTH domain, and a number of C-terminal LRRs. The 
best studied NLRs are NOD1 and NOD2 that recognize bacterial peptidoglycan and activate 
MAPK and NF-țB through a CARD-dependent recruitment of RIP2 (69;70). The NALP 
proteins, at least some of them, have important roles in activation of pro-inflammatory 
caspases through formation of complexes called inflammasomes. These complexes are 
identified as the NALP1 and the NALP2/NALP3 inflammasomes. The NALP1 
inflammasome consists of NALP1, the adaptor protein ASC, caspase 1 and caspase 5 (71), 
whereas the NALP2/NALP3 inflammasome is composed of NALP2 or NALP3 in addition to 
CARDINAL, ASC and caspase 1 (72).  Both inflammasomes control the processing of the 
pro-inflammatory cytokines IL-1ȕ and IL-18 (3). Interestingly it seems that not only PAMPs 
but also the presence of additional danger signals or DAMPs, e.g. silica crystals, salt 
aluminium crystals, asbestos and uric acid, can be sensed by inflammasomes (73-75). 
 1.2 Antiviral signaling pathways 
Cell signaling comprises a complex system of communication within cells and between cells. 
This communication governs basic cellular activities and coordinates cell actions. The ability 
to respond to extracellular as well as endogenous signals is the basis of important processes 
such as development, immunity, tissue repair, cell growth, metabolic regulation and cellular 
homeostasis. A signal is generally received by a receptor which in turn initiates protein-
protein interactions. One major mechansim in signaling is tyrosine phosphorylation. The 
human genome encodes 90 different tyrosine kinases (76), which may be divided into 
receptor-type and non-receptor-type tyrosine kinases. These proteins are crucial to important 
cell signaling pathways, e.g. the Epidermal growth factor receptor (EGFR), which regulates 
cellular growth. Increased activation of EGFR is strongly related to development of cancer 
(77), illustrating the importance of tyrosine kinases in cell signaling.  
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Viral recognition by PRRs initiate the activation of signaling pathways that lead to production 
of type I IFNs and cytokines. Two types of PRRs that recognize invading viruses have been 
identified; TLRs and RLHs. Virus sensing TLRs including TLR3, TLR7, TLR8 and TLR9 are 
localized on intracellular vesicles like endosomes/lysosomes suggesting that these TLRs 
recognize viral particles upon internalization and lysing of viruses. RLHs on the other hand 
detect viral components in the cytoplasma. In order to initiate downstream signaling 
pathways, TLRs and RLHs interact with adaptor proteins through TIR domains and CARD 
domains, respectively. The adaptor proteins utilized by TLRs are TRIF, MyD88, MAL, 
TRAM and SARM. However, the TLR signaling pathways are commonly divided into TRIF- 
dependent and MyD88-dependent signaling. The RLHs recruit the adaptor protein MAVS to 
mount antiviral signaling. 
 1.2.1 TRIF-dependent antiviral signaling 
TLR4 is able to signal through TRIF. Still, TLR3 is the only TLR that exclusively utilizes 
TRIF to initiate signaling (38). In response to stimulation by dsRNA or poly IC, TLR3 
recruits TRIF directly to its cytoplasmic TIR domain initiating a signaling cascade that 
activates several transcription factors including IRF3, NF-țB, AP-1 (19;22), and probably 
additional unidentified transcription factors. IRF3 controls transcription of type I IFN genes, 
whereas NF-țB and AP1 regulate expression of genes encoding inflammatory cytokines. 
TRIF forms a complex (either directly or indirectly) with the cytoplasmic adaptor molecule 
TNF-receptor associated factor 3 (TRAF3) and recruits non-canoncial IKKs, TBK1 and IKKİ
(also called IKKi) (78-81). This in turn results in phosphorylation of IRF3 on several sites. 
Phosphorylated IRF3 forms a dimer that translocates into the nucleus to induce expression of 
immune effector genes, such as IFN-ȕ (82-85) and  the chemokine IP10 (86;87).   
The NF-țB family consists of five members: Rel A (p65), Rel B, C-Rel, p105 (precursor of 
p50) and p100 (precursor of p52). NF-țB proteins form homo- or heterodimers to regulate the 
expression of effector molecules (88). The most frequently activated form of NF-țB in TLR 
responses is a heterodimer composed of Rel A and p50 (89). Under unstimulated conditions, 
NF-țB is sequestered in the cytoplasma through interaction with inhibitory IțB proteins. 
Alternative to IRF3 activation, TRIF may induce the NF-țB pathway through the K63 linked 
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ubiquitin ligase TRAF6. TRAF6 activates TAK1 in an ubiquitin dependent manner (90;91). 
Subsequently TAK1, which is a member of the MAPKKK familiy, activates canoncial IKKs 
(IKKĮ and IKKȕ). This leads to the phosphorylation and degradation of IțBs, nessecary for 
NF-țB to enter the nucleus. At the same time TAK1 is able to activate the MAPK pathway 
including JNK, p38 and ERK leading to phosphorylation and activation of AP1 transcription 
factors. Moreover, the C-terminal region of TRIF exhibits RHIM motifs which bind RIP1. 
RIP1 is involved in TNFR-mediated NF-țB activation and forms complex with TRAF6 and 
TAK1 (92;93). Thus the interaction between TRIF and both TRAF6 and RIP1 is likely to be 
important for maximal NF-țB and MAPK activation.
 1.2.2 MyD88-dependent antiviral signaling 
TLR7, 8 and 9 are able to detect viral patterns and initiate antiviral signaling. In contrast to 
TLR3, these PRRs interact with the adaptor protein MyD88 in response to ligand recognition. 
Upon interaction with TLR7 and TLR9, MyD88 immediately recruits members of the IL-1R 
associated kinase (IRAK) familiy (IRAK1 and IRAK4). The signaling pathways downstream 
TLR7/TLR8/TLR9/MyD88 may be divided into NF-țB dependent -, IRF7 dependent - and 
IRF5 dependent signaling. For activation of NF-țB, the IRAK family recruits TRAF6 which 
subsequently activates TAK1 in the same manner as decsribed above for TRIF-dependent NF-
țB activation.  
IRF7, which is the IRF family member most homologous to IRF3, potentially activates 
transcription of IFN-Į and IFN-ȕ, particularly in pDCs. MyD88 has been shown to be 
essential for the activation of IRF7 by TLR7, TLR8 and TLR9 (94-96). However, unlike IRF3 
the expression of IRF7 is not ubiquitously, but it is induced in response to viral infections 
(84;97). IRF7 has been found in complex with MyD88, IRAK1, IRAK4, and TRAF6. 
Moreover, IRAK1 but not IRAK4 was shown to phosphorylate IRF7 (95;98). IKKĮ is able to 
phosphorylate IRF7 in vitro, but the functional relationship between IKKĮ and IRAK1 is not 
known (99). Additionally, TRAF3 is required for IRF7 activation and type I IFN production 
in response to TLR7 and TLR9 ligands (80). TBK1 and IKKİ are reported to phosphorylate 
IRF7, thus activating the IFN-Į promoter (79). However, TLR9-mediated IFN-Į production is 
unaffected in TBK1 and IKKİ deficient mice (95).  
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MyD88 signaling also leads to activation of IRF5, which is essential for the induction of a 
range of pro-inflammatory genes such as IL-6, IL-12 and TNF-Į. Recent studies show that 
IRF5 is subjected to K63-linked ubiquitination by TRAF6, and that interaction with IRAK1 is 
required for the ubiquitination and activation of IRF5 (100). Ultimately, IRF5 translocates to 
the nucleus where it binds to ISRE motifs in promotor regions of cytokine target genes (101). 
IRF4 negatively regulates IRF5 by competing for MyD88 (102).
 1.2.3 RIG-I-dependent antiviral signaling 
The recent characterization of RIG-I has defined a novel antiviral signaling pathway. RIG-I 
activates NF-țB and IRF3 through its N-terminal CARD domains. Upon viral recognition 
RIG-I recruits the adaptor protein MAVS through CARD-CARD interaction (64-67). MAVS 
is anchored to the mitochondrial outer membrane through a hydrophobic C-terminal region 
(66). Its mitochondrial localization is apparently crucial for downstream signaling. The 
NS3/4A protease of hepatitis C virus (HCV) cleaves the C-terminal region of MAVS causing 
disruption in RIG-I-mediated IRF3 activation, probably due to mislocalization of cleaved 
MAVS from the mitochondria (65;103). MAVS is found to associate with TRAF3 
(80;81;104). TRAF3 recruits the downstream kinases TBK1 and IKKİ which regulates the 
phosphorylation of IRF3 and IRF7 (78;79). Phosphorylation of IRF3 and IRF7 induces the 
formation of homodimers or heterodimers that translocate into the nucleus for transcription of 
type I IFN genes (96).  MAVS also interacts with the death domain-containing adaptor FADD 
which is involved in death receptor signaling (64). FADD forms a complex with caspase-8 
and caspase-10 and is responsible for the activation of NF-țB downstream of MAVS (105). 
Very recently, MAVS and RIG-I were found to associate with the autophagy components 
Atg5-Atg12 (106), suggesting a link between innate immunity and autophagy. 
 1.2.4 TLR3 and RIG-I signaling: converging pathways 
TLR3 and RIG-I are crucial to the innate immune response against viruses. Even though 
TLR3 signals from intracellular vesicles and RIG-I signals from the cytoplasma, both initiate 
the production of type I IFNs mainly through the activation of IRF3. The phosphorylation of 
IRF3 is mediated by TBK1 and IKKİ. However, it remains unclear how these two kinases are 
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activated. Other members of the IKK family such as IKKĮ and IKKȕ are phosphorylated by 
members of the MAPKKK family, which in turn are activated by TRAF6. Despite of the 
requirement for TRAF6 in TLR-mediated IKKĮ/ȕ activation, activation of IRF3 downstream 
of TRIF is independent of TRAF6 (107). TRAF3 was originally identified many years ago as 
a protein that binds CD40, a TNFR family member important for adaptive immune responses 
(108;109). Later studies showed that TRAF3 was required for TLR3-mediated IRF3 
activation, but not NF-țB activation. Thus, TRAF3 was important for TRIF-dependent 
responses (80). Also, MAVS, the RIG-I adaptor protein, has been shown to bind TRAF 
molecules through TRAF interacting motifs (TIMs) (67;104). Thus, multiple viral receptors 
may bind TRAF3 through direct or indirect mechanisms making TRAF3 a converging point 
for antiviral signaling pathways leading to IRF3 activation and type I IFN production. TRAF3 
was also found to be required for IRF7 activation in response to TLR7 and TLR9 signaling 
(80), extending the role of TRAF3 in antiviral responses. The nature of the interaction 
between TRAF3 and other components of antiviral signaling pathways is to a large extent 
unknown. However, the deubiquitinase DUBA was recently shown to deubiquitinase TRAF3 
and by this suppress RIG-I-mediated signaling (110). It has been speculated that TRAF3, like 
TRAF6, acts as an E3 ubiquitin ligase in antiviral signaling (110;111). Very recently, it was 
shown that TRAF3 is an adaptor that links an ubiquitin ligase complex to NIK, thus acting as 
an adaptor and not an E3 ligase in this process (112). Another protein, TRAF associated NF-
țB activator (TANK), has been shown to interact with TBK1 and IKKİ (113;114). This 
suggests that a multimeric complex comprised of at least TRAF3, TANK, TBK1 and IKKİ
might be important for both TLR3 and RIG-I-mediated phosphorylation of IRF3. 
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Figure 3: Sensing of viral dsRNA by TLR3 and RLHs. TLR3 binds dsRNA in endosomal compartments and 
recruits the adaptor protein TRIF. Signaling from TLR3 activates NF-țB through TRAF6 and the IKK complex, 
or IRF3 through TBK1/IKKİ. RLHs recognize viral RNA in the cytoplasma and recruits the mitochondrial 
adaptor protein MAVS. RLH-dependent signaling activates NF-țB and IRF3 via the TRAF6/IKK complex or 
TBK1/IKKİ, respectively.  Both pathways induce production of type I IFNs. During an HCV infection, both 
TRIF and MAVS are cleaved and inactivated by the HCV NS3-4A protease (adapted from Meylan et al. 2006 
(115)). 
 1.2.5 Accessory molecules in antiviral signaling 
Proteins that accompany and assist other proteins, e.g. in activation and interaction, are 
commonly termed accessory molecules. Accessory molecules are required for recognition of 
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PAMPs, subsequent signaling and regulation of immune responses. Several accessory 
molecules have been described for TLR signaling, regulating events on the cell surface, e.g.
MD2, or in the ER, e.g. UNC93B, and by acting directly on TLR ligands, e.g. CD14 (30;116-
118). Recently, a number of accessory molecules have been identified and shown to act in 
discrete subcellular compartments at different levels of the signaling pathways leading to 
IRF3 activation and IFN-ȕ production. A protein termed suppressor of IKKİ (SIKE) was 
identified as a suppressor of both TLR3 and RIG-I-dependent IRF3 pathways. SIKE interacts 
with TBK1 and IKKİ and inhibits both RLH- and TLR-dependent IRF3 activation by 
preventing interactions between IKKİ or TBK1 with TRIF, RIG-I and IRF3. In contrast, 
SIKE has no effect on NF-țB activity (119). Also DEAD box protein 3 (DDX3) was shown 
to alter TBK1-and IKKİ-mediated IRF3 activity. The vaccinia virus protein K7 inhibits TLR- 
and RIG-I-triggered IFN-ȕ induction by preventing TBK1- and IKKİ-mediated IRF3 
activation, and DDX3 was identified as a target for K7. Impairment of DDX3 attenuates 
antiviral responses to dsRNA and SV, and DDX3 associates with IKKİ upon virus infection 
(120). In addition, SINTBAD and NAP1 have been proposed to link TBK1 and IKKİ to 
virus-activated signaling cascades (121;122). Hence, SIKE, DDX3, SINTBAD and NAP1 
represent novel regulators of antiviral kinases; SIKE functions to suppress TBK1 and IKKİ
activity, whereas DDX3, SINTBAD and NAP1 positively alter their function.  
The RIG-I adaptor protein, MAVS, is anchored to the mitochondrial outer membrane. A 
novel protein that also localizes to the mitochondrial outer membrane was recently identified 
and termed mediator of IRF3 activation (MITA). MITA was shown to induce IRF3 activation 
and be important for antiviral immune responses. Morover, MITA interacts with MAVS and 
IRF3, and recruits TBK1 to the complex. TBK1 phosphorylates MITA in vitro, an event that 
is required for MITA-induced IRF3 activation (123). Another study identified the same 
protein as an ER resident protein and termed it STING (124). In this study, STING was found 
to activate NF-țB and IRF3, and to induce type-I IFNs. Ablation of STING abrogates RIG-I 
dependent antiviral responses, but does not affect the TLR3 pathway. Interestingly, STING 
interacts with translocon-associated proteins, and the translocon appears to be important for 
antiviral response. A member of the NOD-like receptors, NLRX1 (also called NOD5), 
contains a putative mitochondrial targeting sequence within the first 20 amino acids instead of 
the typical N-terminal CARD domain. A recent study proposed that the NACHT domain of 
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NLRX1 interacts with the CARD domain of MAVS, suggesting that NLRX1 competes with 
RLHs. NLRX1 was observed to reside on the mitochondrial outer membrane. Overexpression 
of NLRX1 interferes with SV-induced RLH-MAVS interaction, as well as RLH- and MAVS-
induced IFN-ȕ production. Depletion of NLRX1 induces type-I IFN production and decreases 
viral replication. The TLR3-dependent pathway is not affected by NLRX1 (125). Still, the 
exact function of NLRX1 is controversial. It has also been reported that NLRX1 amplifies 
NF-țB and JNK pathways induced by TNF, apparently through increased generation of 
reactive oxygen species (ROS) in the mitochondria. This study did not report any function of 
NLRX1 on the IFN-ȕ or NF-țB pathways (126). Nevertheless, MITA/STING and NLRX1 are 
novel regulators of RLH-dependent antiviral signaling. Both appear to modulate the function 
of signaling components on membranes, however, they display opposite effects on antiviral 
responses.
 1.3 PRR-stimulated responses 
Signaling from PRRs leads to the induction of cytokine genes and establishment of innate 
immunity. TLR and RLR responses stimulate both production of pro-inflammatory cytokines 
including IFNs, IL-1, TNFĮ and IL-12, and anti-inflammatory cytokines such as IL-10. 
Antiviral signaling typically activates IRF3 and IRF7 which regulate the expression of type I 
IFNs (IFN-Į and IFN-ȕ). DCs produce high amounts of type I IFNs leading to an antiviral 
state in the cells. The antiviral state is characterized by inhibition of both viral replication and 
cell proliferation, and also enhancement of the ability of NK cells to lyse virally infected cells. 
 1.3.1 Type I interferons and the antiviral state 
In the late 50s a soluble factor produced by cells in response to inactive, non-replicating virus 
was described to inhibit subsequent infection with live virus (127-129). Today this interfering 
factor is known as Type I IFN (IFN). The type I IFN familiy consists of a growing group of 
IFN proteins wherein the best describedtypes are IFN-Į and IFN-ȕ (130). Several IFN-Į
subtypes are found, whereas IFN-ȕ is encoded by only a single gene (131). The transcriptional 
regulation of type I IFNs is best understood for IFN-ȕ. In response to virus or viral 
components a complex termed the enhanceosome is assembled on the IFN-ȕ promoter 
(132;133). The enhanceosome comprises at least three classes of transcription factors; ATF-2, 
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NF-țB and IRF3. Once secreted, IFN-ȕ binds the IFN-Į/-ȕ receptor (IFNAR) in an autocrine 
and paracrine manner, initiating a positive feedback loop that results in further production of 
type I IFNs. The IFNAR, which consists of IFNAR-1 and IFNAR-2, activates the janus 
kinase (JAK) family members JAK1 and Tyk2. This in turn leads to phosphorylation of signal 
transducer and activator of transcription1 (STAT1) and STAT2. STAT1 and STAT2 form a 
complex with IRF9, termed interferon stimulated gene factor 3 (ISGF3), which initiates the 
transcription of more than 300 IFN stimulated genes (ISGs) on interferon sensitive response 
elements (ISRE), including genes encoding 2ƍ-5ƍ-oligoadenylate-synthetase (OAS), PKR 
(double-stranded RNA–dependent protein kinase), MxA (myxovirus resistance A), ISG15, 
IRF-7 and IP-10 and more. These proteins elicit an antiviral state by inhibiting different 
stages of virus replication and spread (134).  
Among the numerous antiviral mechanisms mediated by ISG encoded proteins, four main 
effector pathways of IFN-mediated antiviral response have been distinguished; the Mx 
GTPase pathway, the 2´-5´-oligodenylate-synthetase (OAS)-directed ribonuclease L pathway, 
the PKR pathway and the ISG15 ubiquitin-like pathway. These pathways individually modify 
protein function, block viral transcription, degrade viral RNA and inhibit translation. ISG15, 
which is one of the most highly induced ISGs, was initially identified as an ubiquitin homolog 
(135). ISG15 mediates an IFN-induced ubiquitin-like protein response referred to as 
ISGylation. Through the action of specific enzymes, ISG15 is activated and conjugated to 
substrate proteins. All components of the ISGylation pathway are induced by type I IFNs. 
Through conjugation to target proteins, ISG15 modifies important mechanisms of the host 
immune system and the viruses, e.g. virus-mediated degradation of IRF3 which is prevented 
by ISGylation (136). The Mx GTPases belong to a class of proteins termed guanine 
hydrolysing proteins that is involved in scission to mediate vesicle budding, oranogenesis and 
cytokinesis. In humans, only MxA have been shown to elicit antiviral activity. Upon IFN-
mediated induction, MxA proteins accumulate as oligomers in the cytoplasma where they 
partly associate with a subcompartment of the ER (137). During viral infection, MxA 
monomers are released and bind viral components such as nucleocapsids. Consequently the 
virus is trapped and prevented from replicating at early time points (138). MxA may for 
instance associate with subunits of the influenza virus polymerase, thus inhibiting viral gene 
transcription (139). The OAS proteins are expressed at low levels in unstimulated cells, but 
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are induced by virus infection. They activate RNase L which in turn cleaves mRNA 
(140;141). Hence, OAS in combination with RNase L constitutes an antiviral RNA decay 
pathway. RNA degraded by RNase L can activate other PRRs, including RIG-I and Mda5, 
thus inducing type I IFN gene expression. PKR is constitutively expressed, and is also 
induced by type I IFNs (142). It accumulates in the cytoplasma as an inactive monomer, and 
is activated directly by viral RNA and other ligands (143-145). Activated PKR forms a dimer 
and functions in viral defence by phosphorylating eukaryotic translation initiation factor 2Į
(EIF2Į), and by that inhibiting translation.
NK cells are an important component of the antiviral immune defence with the ability to 
eliminate virus-infected cells. NK cells are traditionally considered as effector cells with its 
rapid activation and cytotoxic potential. Early activation of NK cells is mediated by cytokines, 
e.g. type I IFNs produced by DCs in the antiviral state. Activated NK cells kill infected cells 
by exocytosis of small proteins such as perforin and granzymes. In addition, activated NK 
cells secrete interferon-Ȗ (IFN-Ȗ) and augment pathogen clearance by macrophages (146;147).  
 1.3.2 PRR-stimulated responses: linking innate and adaptive immunity
Type I IFNs are important for antiviral innate immune responses. In addition, this class of 
cytokines has several effector functions in the development of adaptive immunity. Adaptive 
immune responses are initiated by antigen-presenting cells, such as DCs and macrophages. 
DCs and macrophages arise from monocytes, which circulate in the body and, depending on 
the correct signal, differentiate into DCs or macrophages. It has been reported that IFNĮ/ȕ
may act very early to stimulate DC differentiation from monocytes (148;149). DCs in 
peripheral tissues capture exogenous antigens and PRR ligands, and migrate to the lymph 
nodes to present the processed antigen to naive T lymphocytes via MHC molecules. This 
migration is regulated by PRR-induced chemokines (150-152). Upregulation of the 
chemokine receptor CCR7, which renders DCs sensitive to the chemokines CCL19 and 
CCL21, has been observed in human mDCs upon treatment with Type I IFNs (153). At the 
same time the DCs undergo a maturation process turning them into immunostimulatory 
antigen-presenting cells able to prime effector T cells. Type I IFNs produced after 
internalization of virus or viral nucleic acid, e.g. CpG and dsRNA, has been shown to induce 
phenotypic maturation of DCs, assessed by upregulation of co-stimulatory molecules such as 
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CD40, CD80 and CD86 (154-156). The upregulation of CD40 is markedly diminished in DCs 
from STAT knock-out mice after stimulation with TLR4 and TLR9 agonists. This suggests 
that DC activation upon TLR signals may largely depend on the establishment of an autocrine 
or paracrine positive type I IFN feedback-loop (154;157). Overall, type I IFNs exhibit 
multiple effects on DCs, including differentiation, migration and maturation. 
Besides their influence on DC function, type I IFNs have been implicated in cross-
presentation of viral antigens leading to cell-mediated cytotoxicity and killing of viral-
infected cells. During infection with lymphocytic choriomeningitis virus (LCMV), cross-
presentation occurs by a mechanism that depends on type I IFNs (158). Also, another study 
showed that cross-priming induced by TLR3 and TLR4 ligands is completely dependent on 
Type I IFNs (159). Shulz et al. demonstrated that immunization with virus-infected cells or 
cells containing synthetic dsRNA lead to increase in CD8+ T cell cross-presentation against 
cell-associated antigens, which is largely dependent on TLR3 expression by APCs (46).
 1.4 Regulation of interferon transcription 
The IFN-ȕ gene induction is a highly ordered process and includes tight regulation by several 
different transcription factors. The IFN-ȕ promoter consists of at least four positive regulatory 
domains (PRDs), termed I, II, III and IV. In comparison, the IFN-Į promoter contains only 
PRD I- and III- like elements. IRF family members bind to PRD I and III, NF-țB to PRD II 
and AP1 (also called ATF2/c-Jun) to PRD IV. These transcription factors assemble a complex 
with the high mobility group protein (HMG)-I(Y). This complex is commonly termed the 
enhanceosome, and is responsible for the regulation of interferon transcription. The 
enhanceosome recruits histone acetyl transferases (HATs), including the general-control-of-
amino-acid synthesis 5 (GCN5) and CREB binding protein (CBP), to the nucleosome. 
Histone acetylation leads to the recruitment of a nucleosome modification complex termed the 
Brahma-related gene (BRG)-Brahma (BRM) associated factor (BAF) complex, which forces 
displacement of the nucleosome from the transcription start site. At the same time the 
transcription complex TFIID binds to the promoter. Subsequently, transcription of the IFN-ȕ
gene can take place (160). 
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Figure 4: The enhanceosome. One NF-țB complex (p50 and p65) and two IRF dimers (IRF3 homodimers, IRF7 
homodimers or IRF3-IRF7 heterodimers) bind independently to their respective binding elements. These 
transcription factor complexes cooperatively interact with each other and the co-activators CBP or p300 to form 
the enhanceosome. Assembly of the enhanceosome induces transcription of the IFN-ȕ gene (160). 
                                                                                                                                                                                       
 1.4.1 The IRF family 
To date nine members of the IRF family, IRF1-9, have been identified (161;162). They 
contain a well-conserved N-terminal DNA binding domain (DBD) (162;163) which forms a 
helix-turn-helix and recognizes similar DNA sequences (164). The C-terminal region of the 
IRFs, except for IRF1 and IRF2, comprises an IRF association domain (IAD) which enables 
them to form homodimeric and heterodimeric interactions with familiy members or other 
transcription factors. IADs show structural similarities with Mad-homology 2 (MH2) domains 
of the Smad family of transcription factors (165;166), and Smad 3 was recently found to 
interact with IRF7 for induction of type I IFN production (167). The specificities of IRFs 
appear to be mediated by their cell type specific expression, distinct interaction with other 
IRFs, other transcription factors or cofactors, and discrete regulatory mechanisms. Four of the 
IRFs, IRF1, IRF3, IRF5 and IRF7, are categorized as positive regulators of type I IFN gene 
transcription. IRF3 and IRF7 are the main inducers of type I IFNs and will be discussed in 
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more detail later. In addition, both IRF1 and IRF5 have been implicated in type I IFN gene 
induction by viruses.
IRF5 was identified to be crucial for induction of inflammatory cytokines and type I IFNs by 
all TLRs. Still, studies in knock-out mice revealed that IRF5 is involved in induction of 
cytokines such as IL-6, IL-12 and TNF-Į rather than in type I IFN induction (101). In contrast 
to IRF3 and IRF7, the activation mechanism for IRF5 is poorly understood. It has been shown 
that IRF5 acts in a trimeric complex with TRAF6 and MyD88, and that IRF5 is subjected to 
ubiquitination by TRAF6 (100). Also it has been suggested that IRF5 is activated through 
IRAK kinases, in particular IRAK1 which was required for IRF5 ubiquitination and activation 
(100). In contrast, IRF4 negatively regulates IRF5 by competing for MyD88 (102). 
Nevertheless, the precise role of IRF5 in type I IFN gene induction remains to be assessed.
 1.4.2 The interferonic IRFs: IRF3 and IRF7  
IRF3 and its close homolog, IRF7, are regarded as the main transcription factors for type I 
IFN gene induction by viruses. IRF3 is constitutively expressed in the cytosol. Upon viral 
challenge, it undergoes phosphorylation, dimerization and translocation to the nucleus 
(82;84;168). Potential phosphorylation sites have been identified in the C-terminal region of 
IRF3; serine 385, 386, 396, 398, 402 and 405, and threonine 404.  Based on a crystal 
structure, two models for the activation and dimerization of IRF3 have been presented. One is 
the «phosphorylation-induced dimerization model», where the S385 and S386 of one 
monomer of IRF3 interact with a hydrophobic pocket of another monomer of IRF3 or IRF7 
(166). The other model is called «the autoinhibitory model» and suggests that interaction 
between N- and C-terminal Į-helical structures flanking a ȕ-sandwich IAD core in IRF3 form 
a hydrophobic structure in the inactive state. This structure opens upon multiple 
phosphorylations of the suggested threonine and serines which generate massive negative 
charges (165).  In whatever way, upon an antiviral response the dimeric form of IRF3, either a 
homodimer or a heterodimer with IRF7, translocates to the nucleus where it forms a complex 
with the coactivators CBP and/or p300 and binds to its target DNA sequences in type I IFN 
genes in addition to some cytokine and chemokine genes. The different dimers act 
differentially on the type I IFN gene family members. IRF7 is expressed at low levels in most 
cell types, but is strongly induced by type I IFN responses that includes the IFNAR (84;97). 
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The IFNAR recruits the ISGF3 complex which in turn activates gene expression of IRF7. 
Like IRF3, IRF7 is expressed in the cytosol where it undergoes phosphorylation and 
dimerization upon virus infection. The IRF7 hetero- or homodimer translocates to the nucleus 
to activate gene expression. IRF3 activates the IFN-ȕ gene rather than the IFN-Į genes, 
whereas IRF7 is a strong activator of both IFN-ȕ and IFN-Į genes (96). Recently it was 
demonstrated that IRF3 and IRF7 are involved in the induction of a new class of IFN family 
members, type III IFNs, including IFN-Ȝ1, IFN-Ȝ2 and IFN-Ȝ3. This new class of IFNs shows 
similar biological antiviral function to type I IFNs (169). 
 1.4.3 The ATF/CREB family 
The ATF/CREB family consists of a large group of basic-region leucine zipper (bZIP) 
transcription factors with a diverse set of biological functions. Despite their diverse activities 
they share a common ability to respond to stress signals. Apart from its role in the 
enhancosome, ATF2 is mainly involved in transcriptional control of stress response genes, as 
is ATF3 (170). ATF6 plays a role in the regulation of gene induction upon endoplasmic 
reticulum stress and serum-responses (170-172). CREB and ATF1 regulate transcription in 
response to intracellular cAMP, whereas ATF4 is a negative regulator of cAMP levels (173). 
All ATFs bind to the ATF/CRE consensus sequence TGACGTCA (172). Transcription of 
ATF3 is induced by proinflammatory cytokines and stress signals. Interestingly, in contrast to 
other ATF family members ATF3 has been shown to repress rather than activate transcription 
from promoters with ATF/CRE binding sites (172). In accordance with this, ATF3 was 
recently implicated in regulation of immune responses and was identified as a negative 
regulator of TLR4-elicited signaling (174). 
 1.5 C-Src tyrosine kinase 
In 1911, Peyton Rous observed a microscopic particle, later identified as a virus that could 
induce sarcoma in chicken (175). The virus was named Rous sarcoma virus (RSV). In 1976, 
the RSV genome was found to encode an oncogene nearly identical to a human proto-
oncogene (176). The viral gene v-Src and the human gene c-Src (cellular Src) were shown to 
display differences in their C-terminal sequences. Further studies showed that the proteins 
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encoded by these genes were tyrosine protein kinases (177), and ultimately that v-Src exhibits 
constitutive tyrosine kinase activity (178).
 1.5.1 Domain structure and kinase activation 
The Src family of non-receptor protein tyrosine kinases have been implicated in numerous 
cellular processes, including gene transcription (179;180) adhesion (181), migration 
(182;183), cell cycle control (184-186) apoptosis (187;188), differentiation (189;190) and 
more. The family consists of nine members; Src, Fyn, Yes, Fgr, Lyn, Hck, Lck, Blk and Yrc. 
Src, Yes, Fyn and Yrc are ubiquitously expressed, whereas the others are expressed in more 
restricted patterns (191). In vertebrates all members of the Src family display similar structure 
(178). They show several conserved domains in addition to the tyrosine kinase domain (SH1, 
Src homology 1). The kinase domain is responsible for tyrosine kinase activity and plays a 
crucial role in substrate specificity. The amino acid sequence preferably phosphorylated by c-
Src is EEEIYG/EEFD (192). The SH2 domain binds phosphotyrosine-rich sequences on other 
proteins, whereas the SH3 domain binds proline-rich regions. Some proteins interacting with 
c-Src contains an optimum binding sequence, pYEEI. However, not all proteins binding to the 
c-Src SH2 domain harbours such phosphorylated sequence. All known SH3 ligands carry the 
proline-rich consensus sequence PXXP, and the amino acid adjacent to proline determine the 
specificity of the SH3 domain. In addition the Src proteins consist of an N-terminal variable 
region that is modified by myristotylation and palmitoylation (also called the SH4 domain), as 
well as a flexible tyrosine containing tail (178;193). The N-terminal region is responsible for 
membrane binding. The SH2 and SH3 domains are important for regulation of the catalytic 
activity of the c-Src. In order to stabilize an inactive conformation, the SH3 domain interacts 
with the catalytic domain and the linker region between the catalytic domain and the SH2 
domain. In this inactive state the SH2 domain binds phosphorylated tyrosine 527 (Y527) in 
the C-terminal region. Dephosphorylation of Y527 leads to stimulation of c-Src catalytic 
activity. Hence, the substitution of the tyrosine on position 527 by another amino acid residue 
constitutively activates c-Src (194). However, the regulation of c-Src activity occurs at two 
sites. Phosphorylation of tyrosine 416 (Y416), which is probably mediated by 
autophosphorylation, stimulates maximal activation of c-Src and genreates a binding site for 
SH2 domains of other proteins. Thus the two regulating phosphorylation events of c-Src have 
opposite results; phosphorylation of Y416 in the activating loop of the kinase domain 
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activates the enzyme, whereas phosphorylation og Y527 in the C-terminal region causes its 
inactivation.  
Figure 5: Domain structure and activity model of c-Src. A) The domain structure of c-Src includes a kinase 
domain, a SH2 domain, a SH3 domain and an N-terminal unique region. B) Schematic diagram illustrating 
inactive and active c-Src. In the inactive assembled form, the SH3 domain interacts with the kinase domain and 
the linker region between the kinase domain and the SH2 domain. The SH2 domain binds to phosphorylated 
Tyr527. Dephosphorylation of Tyr527 and autophosphorylation of Tyr416 results in the activation of c-Src. In 
the active form the SH2 and SH3 domains are displaced and free to interact with external ligands (Adapted from 
Young et al. 2001 (195)). 
                                                                                                                                                                                       
 1.5.2 Roles of c-Src in innate immunity  
C-Src was the first proto-oncogene to be identified and also the first protein shown to possess 
intrinsic kinase activity. Its role in tumorigenesis have been extensively studied, and chemical 
inhibitors targeting c-Src PTKs have been developed as potential drugs for cancer treatment. 
Several studies demonstrate that c-Src PTKs may modulate functions of the immune system 
as well. Tyrosine phosphorylation is an important post-translational mechanism that regulates 
diverse intracellular pathways in the innate immune system. The functions of TLRs are 
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modulated by tyrosine phosphorylation of e.g. TLR2, TLR3, TLR4, TLR8, TLR9 and Mal 
(196-203), but the exact molecular mechanisms involved have not been disclosed. 
Nevertheless, it has been shown that inhibition of c-Src PTKs can attenuate sepsis, which is 
caused by excessive production of inflammatory cytokines (204). In particular, c-Src tyrosine 
kinases have been implicated in immune responses induced by LPS. Mice deficient of c-Src 
family kinases Hck and Fgr are resistant to endotoxic shock (205), whereas mice expressing 
constitutively active Hck display enhanced immune responses to LPS (206). Moreover, the c-
Src family member Lyn is activated by LPS, and is coupled to the LPS receptor CD14 in 
human monocytes (207). Another study shows that Hck and Lyn kinase activity is increased 
by LPS, and that inhibition of PTK activity reduces LPS-induced responses including TNF-Į
production in monocytes and macrophages (208-210). Still other studies show that NF-țB
activation is unaffected in macrophages from wild type and hck-/-fgr-/-lyn-/- triple knock out 
mice (211). This indicates that c-Src PTKs may be important, but not critical for LPS 
signaling in monocytes and macrophages.  
During inflammation, tissue cells are important mediators of the host response. Epithelial 
cells can produce host inflammatory effectors such as monocyte chemoattractant protein 1, 
IL-6 and IL-8 in response to inflammatory stimuli (212). These responses are partly regulated 
by c-Src PTKs. In human airway epithelial cells TNF-Į stimulation increases activation of c-
Src (213). In human lung epithelial cells, TNF-Į activates c-Src through protein kinase C 
(PKC) on one hand, and NF-țB-inducing kinase (NIK) via TRAF2 on the other hand. These 
two pathways converge at IKKȕ, suggesting that NIK phophorylate two serine residues on 
IKKȕ, whereas c-Src PTKs phosphorylate two tyrosine residues. IKKȕ in turn activates NF-
țB to induce inflammatory genes (213;214). In conclusion, c-Src PTKs may be important 
mediators of innate immune responses at several levels. However, the specific role of each c-
Src family member is largely unknown.  
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 2 AIMS OF STUDY 
In light of the considerable global health threat that viral infections represent in regard to 
inflammatory diseases and cancer, it was of interest to study the signaling mechanisms 
induced upon the immediate interaction between the host and the virus. It was required to 
delineate signaling components downstream pattern recognition receptors, and study the 
mechanisms regulating the early response to viral infections induced by these receptors. The 
study of molecular mechanisms behind host-virus interactions is important in the 
development of new strategies for antiviral therapeutics and vaccines, as well as cancer 
treatment. This is exemplified through the clinical development of a number of substrate-
based peptidomimetic agents targeting virally encoded proteins, e.g. the HCV NS3/4A 
protease. 
In particular, we aimed to: 
1) Examine if the tyrosine kinase c-Src is involved in TLR3-mediated antiviral signaling, 
and characterize its possible role in dsRNA-induced antiviral responses (Paper I)
2) Characterize the intracellular localization of dsRNA, TLR3 and c-Src, and study the 
uptake mechanisms of dsRNA in monocyte-derived dendritic cells (Paper I).
3) Elucidate if c-Src is important in antiviral responses mediated by the cytoplasmic 
receptor RIG-I, and delineate its possible function in antiviral signaling pathways 
(Paper II).
4) Compare the role of c-Src in activation of IRF3 and IRF5 in TLR-mediated 
transcription (Paper III). 
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 3 SUMMARY OF PAPERS 
PAPER I: Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to 
initiate antiviral signaling 
Viral dsRNA initiates antiviral signaling through TLR3. The signaling pathways downstream 
of TLR3 comprise several components, including kinases. In this paper we examine the role 
of the tyrosine kinase c-Src in TLR3-mediated antiviral signaling. We show that c-Src 
tyrosine kinase is activated by viral dsRNA in human monocyte-derived dendritic cells, and is 
recruited to TLR3 in response to dsRNA. Treatment with c-Src chemical inhibitors reduces 
IRF3 activation. Further, nuclear translocation of IRF3 is abolished in c-Src deficient mouse 
embryonic fibroblasts, as is activation of STAT1, suggesting a role of c-Src in antiviral 
immunity. Expression of a c-Src kinase inactive mutant shows that c-Src elicits its function 
downstream of TRIF. We also demonstrate that c-Src tyrosine kinase conveys and regulates 
dsRNA-mediated Akt activation, but not dsRNA-induced MAPK activation. This shows that 
c-Src differentially regulates TLR3 responses. Studies using confocal scanning microscopy 
reveal that TLR3 is expressed in endoplasmic reticulum in resting cells and that a fraction of 
TLR3 translocates to endosomes/lysosomes upon dsRNA treatment. DsRNA is internalized 
into intracellular vesicles by clathrin-mediated endocytosis and is recognized by TLR3 in the 
endosomal pathway. Moreover, c-Src tyrosine kinase localizes to endosomes/lysosomes 
where it interacts with TLR3/dsRNA in order to transmit antiviral signaling. 
PAPER II: The tyrosine kinase c-Src enhances retinoic acid inucible gene-I (RIG-I)-
elicited antiviral signaling 
TLR3 transmits antiviral signaling from intracellular vesicles such as endosomes/lysosomes. 
However, cytoplasmic sensing of virus or viral products is conveyed by RIG-I like helicases. 
In this paper we study the role of c-Src tyrosine kinase in RIG-I-mediated antiviral response, 
and delineate molecular mechanisms behind the function of c-Src in antiviral signaling 
pathways. We show that c-Src is activated upon infection with Sendai virus (SV). Impairment 
of c-Src through chemical inhibition or transient expression of a c-Src kinase inactive mutant 
attenuates IRF3 activation as well as IP-10 and IFN-ȕ production after SV-infection or 
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expression of RIG-I and its adaptor protein MAVS. Also, treatment with c-Src siRNA impairs 
SV-induced IFN-ȕ synthesis and IRF3 nuclear translocation. Likewise, the induction of IP-10 
and IFN-ȕ mRNA is abolished in c-Src deficient cells, as is nuclear translocation of IRF3. 
Immunoprecipitation studies reveal that c-Src interacts with components of the RIG-I 
signaling pathway, including RIG-I, MAVS, TRAF3 and TBK1, indicating that c-Src 
functions in a signaling complex downstream of RIG-I. Finally, using TRAF3 deletion 
mutants, we show that the interaction between c-Src and TRAF3 occurs within the RING 
domain of TRAF3.  
PAPER III: Activating transcription factor 3 is regulated by c-Src tyrosine kinase and 
confers differential gene expression downstream Toll-like receptors 
Transcription of cytokines which modulate immune responses is regulated by a complex 
network of transcription factors, including several members of the IRF family. In this study 
we compare the effect of c-Src inhibition on TLR-mediated IRF-3 and IRF-5 activation. 
Interestingly, we find that chemical inhibition of c-Src enhances unmethylated CpG-induced 
IRF5 activation, whereas it has the opposite effect on CpG-induced IRF3 activation. 
Moreover, chemical inhibition of c-Src attenuates transcription of the IRF5-regulated gene IL-
6 in response to CpG, whereas transcription of the IRF3-regulated gene IP-10 is elevated. On 
the other hand, we show that inhibition of PI3-kinase reduces both CpG-mediated IRF3 and 
IRF5 activation. Also PI3-kinase inhibition attenuates mRNA transcripts of IL-6 and IP-10, 
suggesting that c-Src and PI3-kinase exert distinct roles in the regulation of IRF5 activation. 
Next, we find that c-Src inhibition results in enhanced IL-6 mRNA induction for all TLR 
ligands investigated, whereas TLR-elicited IP-10 induction is abrogated. This indicates that c-
Src exerts a similar role downstream of both MyD88-dependent and -independent pathways. 
To extend these findings, we show that the TLR ligands LPS, R484, poly IC and CpG 
enhance IL-6 mRNA induction in c-Src deficient mouse embryonic fibroblasts (MEFs). In 
contrast, levels of IP-10 in response to TLR ligands are reduced in the same cell-line. 
Ultimately, we present that TLR stimulated induction of activating transcription factor 3 
(ATF3) is positively regulated by c-Src. Depletion of ATF3 by siRNA markedly enhances IL-
6 production and attenuates IP10 production upon CpG stimulation, indicating that c-Src 
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regulates intracellular ATF3 levels and through ATF3 differentially affects gene expression 
upon TLR-stimulation.  
33
 4 DISCUSSION 
 4.1 TLR3 translocates to dsRNA containing endosomal compartments 
The innate immune system comprises a complex set of coordinated events necessary to mount 
an immediate defence against invading pathogens. These events include sensing of PAMPs, 
uptake of the pathogen, and signal transduction leading to the induction of immune response 
genes. Upon infection with certain viruses, e.g. EMCV and West Nile viruses, viral dsRNA is 
recognized by TLR3. In paper I we studied the dynamics of viral dsRNA internalization in 
human mDCs by confocal microscopy. We observed that dsRNA was internalized into 
vesicles that were transported from the cell periphery towards the centre of the cell and 
subsequently trafficked into tubular structures identified as lysosomes. The fluorescently 
labelled dsRNA sequence (dsRNA-Cy5) used in this study corresponds to a sequence from 
human rhinovirus. Leonard et al. reported that it requires a dsRNA length of at least 40 to 50 
base pairs to bind a TLR3-ECD dimer and induce signaling (215). On the other hand, it has 
previously been shown that shorter chains of poly IC and even oligomeric IC can induce 
receptor signaling (216). The dsRNA-Cy5 sequence used in paper I is only 34 base pairs and 
could be unable to bind TLR3 and initiate antiviral response. Moreover, the fluorescent Cy5 
dye is a bulky label. This may affect the binding between the ligand and the receptor. We 
proved that the sequence was biologically active, as it stimulated IFN-ȕ production in TLR3 
expressing cells and induced IFN-ȕ and TNF in human mDCs. Finally, we found that dsRNA 
co-localized with markers for early and late endosomes/lysosomes, and showed extensively 
overlap with CpG-DNA, which is reported to be internalized by endocytosis (40). 
Collectively, these results show that the TLR3 ligand dsRNA is internalized into mDCs by 
endocytosis and is trafficked through the endosomal pathway.  
The general believe has been that the nucleic acid recognizing TLRs, TLR3, TLR7, TLR8 and 
TLR9, localize to endosomal membranes and recognize their ligands in the endosomal lumen. 
However, only TLR9 is unambiguously shown to localize to endosomes (39;40). The same 
study stated that TLR9 is expressed in the endoplasmic reticulum (ER) in nonstimulated cells. 
Likewise, we demonstrated in paper I that TLR3 was expressed in the ER in resting cells, 
both in HeLa cells stably expressing TLR3 and in human mDCs. In cells stimulated with 
dsRNA, a fraction of TLR3 translocated to endosomes/lysosomes. The mechanism by which 
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TLR3 translocates from the ER to the endosomes/lysosomes still remains unexplained. Newly 
synthesized proteins are normally released from the ER and travel to different compartments, 
e.g. endosomes/lysosomes or the plasma membrane, through the Golgi apparatus via the 
secretory pathway. As presented in paper I, Golgi-dependent mechanisms could not be 
detected for TLR3 translocation. Thus, TLR3 could be trafficked through direct delivery of 
ER membranes to endosomes, similar to the mechanism suggested for ER-mediated 
phagocytosis (217;218). However, another study failed to observe contact between the ER 
membrane and the plasma membrane. The same study showed that the plasma membrane is 
the main constituent of phagosomes, and that ER membranes are almost absent in 
phagosomes/endosomes (219). Hence, it is possible that other mechanisms may be 
responsible for the translocation of TLR3. If it is a signal-mediated event, TLR3 could either 
receive a signal elicited by dsRNA that triggers trafficking to the endsomes/lysosomes, or an 
additional molecule could trigger translocation of TLR3. However, TLR9 travels normally to 
the endosomes in CpG-DNA treated cells even in MyD88 deficient DCs (40). Therefore, if 
translocation of TLR9 is mediated by CpG-DNA, it occurs in a MyD88-independent way. 
Recently, autophagy was reported to be necessary for TLR7 dependent recognition of certain 
ssRNA viruses and for production of IFN-Į in pDCs, by facilitating transport of cytosolic 
viral replication intermediates into lysosomes (220). It is possible that autophagy mediates 
signal-induced or constitutive uptake of TLR3 from the ER or the cytosol. In that way, TLR3 
could be trafficked into the endosomal pathway through autophagy. Interestingly, the ER-
resident membrane protein UNC93B was shown to interact with TLR3, 7 and 9, and to be 
required for appropriate signaling from these TLRs (118). Very recently, it was demonstrated 
that neither TLR7 nor TLR9 exits the ER in mice carrying a mutation in the UNC93B gene 
(24). Still, it is possible that TLR3 and TLR7/TLR9 travel by independent mechanisms, and 
that these processes are constitutive. Hence, it would be interesting to explore if the 
translocation of TLR3 from ER to endosomes/lysosomes is regulated, and determine receptors 
and signaling pathways that might be implicated.  
 4.2 C-Src tyrosine kinase associates with TLR3 on dsRNA containing 
endsomes/lysosomes
In paper I, we found that c-Src tyrosine kinase was activated and recruited to TLR3 in 
response to dsRNA. Therefore, we prompted to study the subcellular localization of c-Src in 
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cells triggered by dsRNA. In particular, we addressed the cellular site of interaction between 
c-Src, TLR3 and dsRNA. In accordance with previous reports (221;222), we observed that c-
Src was expressed on the plasma membrane and in intracellular vesicles. In paper I, we found 
that treatment with dsRNA induced increased co-localization between c-Src and markers for 
early endosomes and late endosomes. Hence, endosomes/lysosomes might be the cellular site 
of action for c-Src in TLR3 dependent responses, given that c-Src interacts with TLR3 and/or 
TRIF upon dsRNA challenge to convey antiviral signaling. In this regard, we demonstrated 
that TLR3 encircled the surface of vesicles containing dsRNA in their lumen. These vesicles 
were identified as endosomes, as they were positive for the PI-3 phosphate-binding module 
FYVE, which is expressed on early endosomes. TLR3 was also found on vesicles positive for 
the late endosomal marker in dsRNA-stimulated mDCs. Interestingly, TLR3 co-localized with 
c-Src on these vesicular structures. Hence, we believe that a fraction of TLR3 translocates to 
the endosomal pathway where it recognizes dsRNA and associates with downstream signaling 
components, including c-Src, leading to an active signaling complex on the cytoplasmic tail 
of TLR3. Importantly, the TLR3-ECD binds dsRNA only at acidic pH (pH 6,5 and below) 
(215;216), indicating that TLR3 binds its ligand in endosomal compartments. There are 
several examples on signaling that occurs from endosomal membranes. Epidermal growth 
factor (EGF) receptors are known to preserve their dimerization and kinase activity on 
endosomes (223;224), and the kinases Raf, MEK and p42/44 MAP kinase are also associated 
with endosomes (225). Our findings regarding subcellular localization are based on confocal 
studies using markers for early and late endosomes. However, the marker for late endosomes 
also stains lysosomes, which makes it difficult to assess the exact site of TLR3 signaling 
within the endosomal pathway. The acidic environment in the endosomes/lysosomes is 
important as it allows for the degradation/uncoating of viruses and bacteria. Some viruses that 
penetrate through clathrin-mediated endocytosis fuse with the endosomal membranes in 
response to the pH drop, either in the early (pH 6,5 -6,0) or the late (pH 6,0 – 5,5) endosome 
(226). Subsequently the viral genetic material is released into the cytoplasm, thus avoiding 
degradation and detection by TLRs. Hence, the exact localization of TLRs within the 
endosomal pathway could be important. Based on the homology between TLR3 and TLR9, it 
is likely that TLR3-mediated signaling occurs from the same cellular compartment as TLR9-
mediated signaling. A study by Honda et al. shows that retention of CpG in endosomal 
vesicles is required for activation of IRF7 and IFN-Į production through TLR9 and MyD88 
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(227). Very recently, a study showed that conformational changes induced by CpG-DNA 
resulted in close apposition of the cytoplasmic signaling domains of TLR9 on endosomes 
(228), implying that TLR9 resides on this subcellular compartment when recruiting 
downstream signaling components. On the other hand, a study by Park et al. reported that 
proteolytic cleavage of TLR9 is a prerequisite for TLR9 signaling, implying that the signal is 
transmitted from the lysosomes (25). Nevertheless, it has been suggested that this pathway is 
a continuum in that the transitions from early endosomes to late endosomes and lysosomes 
involves transient interactions that occurs continuously (229). The exact site of signaling from 
TLR3 within the endosomal pathway remains to be explored, and may not have any 
implication for TLR3-mediated responses. 
Figure 6: Schematic summary of paper I. C-Src tyrosine kinase is activated by dsRNA and associates with 
TLR3 upon dsRNA challenge. A fraction of TLR3 translocates from the ER to the endosomal pathway where it 
recognizes dsRNA and recruits downstream signaling components, including c-Src. C-Src is important for 
dsRNA-induced IRF3 phosphorylation and nuclear translocation.  
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 4.3 C-Src tyrosine kinase is important for antiviral gene induction in response to 
diverse viruses 
Upon ligand recognition, TLR3 recruits the adaptor protein TRIF to its cytoplasmic TIR 
domain to initiate antiviral signaling cascades including several kinases ultimately leading to 
activation of IRF3 and production of type I IFNs. Tyrosine phosphorylation regulates diverse 
intracellular pathways in the immune system, and is reported to modulate functions of TLRs 
and their signaling components, e.g. TLR2, TLR3, TLR4, TLR8, TLR9 and Mal (196-203). 
In particular it was shown that mutations of two specific tyrosine residues within the 
cytoplasmic domain of TLR3 affected dsRNA-mediated induction of the human 561 gene, 
which is regulated by IRF3 (201;202). In paper I, we investigated the role of c-Src tyrosine 
kinase in dsRNA-induced responses. A major part of the insight into the biology of c-Src 
family kinases (SFKs) is provided from loss-of-function studies in mouse. Mice carrying 
mutations in all of the known SFKs have been generated (205). C-Src was the first SFK to be 
mutated. The main phenotype associated with this mutation was a bone remodelling disease 
termed osteopetrosis (190). This is the only severe phenotype observed due to a mutation in a 
single SFK, suggesting that different SFKs may compensate for each other. C-Src, Yes and 
Fyn are often co-expressed in the same cell type, and it is reported that at least in some cells 
these kinases are able to compensate for the loss of the other related kinases. Hence, it might 
be complicated to study specific functions of SFKs by genetic knockout (230).  In our study, 
we used mouse embryonic fibroblasts (MEFs) devoid of c-Src, Yes and Fyn (SYF) and SYF 
cells in which c-Src has been introduced (c-Src) (185). Crossing of Src family mutants leads 
to more severe phenotypes compared to single mutants. Importantly, c-Src/Yes and c-Src/Fyn 
mutants die shortly after birth, whereas the Yes/Fyn mutant is viable but develop a renal 
disease (230). Hence, SYF and c-Src MEFs enabled us to study the function of c-Src. In 
paper I, we demonstrated that c-Src was essential for IRF3 activation and nuclear 
translocation, as assessed using c-Src chemical inhibitor and cells devoid of c-Src. We 
showed that c-Src modulated IFN-ȕ production downstream the TLR3 adaptor TRIF. 
Activation of IRF3 and production of type I IFNs are crucial to build an immediate antiviral 
response (160;231). Collectively, the results from paper I indicate that c-Src is an important 
component of TLR3-mediated innate antiviral defence mechanisms.   
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TLR3 was the first pattern recognition receptor characterized that was capable of signaling to 
IRF3 and NF-țB in response to dsRNA. However, in vivo antiviral responses to several 
viruses were found to be similar in TLR3 deficient mice compared to wild type mice (47). 
Hence, it soon became obvious that other dsRNA receptors may exist. The identification of 
the cytoplasmic PRRs, RIG-I and Mda5, revealed novel understanding of innate antiviral 
signaling pathways. In paper II we showed that c-Src tyrosine kinase has a functional role in 
RIG-I-mediated antiviral responses, thus modulating activation of IRF3 and production of 
type I IFNs through two distinct signaling pathways. Sendai virus (SV), which is a ssRNA 
virus of the paramyxoviridae family, induces antiviral gene expression through RIG-I 
(232;233). We found that SV activated c-Src tyrosine kinase, implying that c-Src is involved 
in RIG-I-mediated signaling. In contrast to poly IC, which activates c-Src within 1 hour, 
optimal activation of c-Src upon SV infection occurred after 8-12 hours. The difference in 
kinetics of activation is likely due to the necessity of viral endocytosis followed by its release 
into the cytosol for replication. We confirmed the role of c-Src in RIG-I dependent responses 
by using chemical inhibition, expression of kinase inactive c-Src and downregulation of c-Src 
mRNA by siRNA. Impairment of c-Src function abrogated IRF3 activation and production of 
the IRF3-regulated genes IFN-ȕ and IP10. Also, IFN-ȕ and IP10 transcription were 
significantly reduced in cells devoid of c-Src, as was nuclear translocation of IRF3. The effect 
of c-Src inhibition on IRF3 activation and IFN-ȕ production could be due to effects of c-Src 
inhibition on SV entry or replication. However, we demonstrated that the mRNA levels of the 
SV-P gene were largely unaffected by c-Src chemical inhibition and in c-Src deficient cells. 
Taken together, the results presented in paper I and paper II imply that c-Src contributes to 
TLR3- and RIG-I-dependent signaling pathways. This suggests that c-Src may be involved in 
antiviral mechanisms induced by different PRRs and play a broader role in innate defence 
against diverse viruses.
 4.4 C-Src tyrosine kinase participates in a multicomponent signaling complex to 
regulate antiviral gene expression 
In paper II, we found that molecular components of the RIG-I signaling pathway, RIG-I and 
MAVS, induced IRF3 dependent transcription that involved c-Src kinase activity. This was 
demonstrated by the ability of kinase inactive c-Src to suppress RIG-I- and MAVS-stimulated 
IRF3 activity and IFN-ȕ and IP10 mRNA induction. Hence, c-Src seems to participate 
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downstream of RIG-I and its adaptor protein MAVS in antiviral responses. In paper I, found 
that c-Src acted downstream of or at the level of TRIF. This was demonstrated by the ability 
of kinase inactive c-Src to abbrogate TRIF-induced IFN-ȕ production. TRAF3 has been 
reported as a critical molecule integrating TLR-dependent and -independent antiviral 
responses (80;81). As c-Src appears to be involved in both TLR3 signaling and RIG-I 
signaling, it is reasonable to speculate that c-Src and TRAF3 somehow collaborate in the 
regulation of IRF3 activity and IFN-ȕ production. In light of that, we found that c-Src 
physically interacted with TRAF3 (paper II). TRAF3 is previously reported to interact with 
several nonrelated kinases, including TBK1 and IKKİ which phosphorylate IRF3, IRAK1 
which mediates MyD88 dependent pathways, NIK that activates the NF-țB pathway, and 
PKR that is known to bind dsRNA (80;234). NIK has been demonstrated to specifically bind 
to the TRAF domain of TRAF3. Still, the molecular mechanisms behind the interactions 
between TRAF3 and TBK1, IKKİ, IRAK1 and PKR are not reported. We sought to explore 
the molecular determinants behind the interaction between TRAF3 and c-Src. We found that 
c-Src specifically bound to RING and zink-finger domains within TRAF3. In contrast, we 
observed that MAVS specifically bound the TRAF domain of TRAF3, consistent with a 
previous report showing that MAVS contains a TRAF interacting motif (TIM) (104). This 
illustrates that the different TRAF3 domains may harbour functional specificity in antiviral 
responses mediated by c-Src and MAVS. Moreover, different modular domains may link 
different kinases (NIK and c-Src) to TRAF3. Taken together, c-Src tyrosine kinase elicits its 
function in RIG-I dependent signaling downstream of MAVS, probably at the level of TRAF3 
to which it specifically interacts with the RING domains. It is likely that TRAF3 is the 
converging point for c-Src-mediated regulation of TLR-dependent and -independent IRF3 
activation and IFN-ȕ production. 
In addition to its interaction with TRAF3, we found that c-Src physically associated with 
other components of the RIG-I pathway, including RIG-I, MAVS, and TBK1. The results in 
paper II suggest that c-Src may be organized into IRF3-activating signaling complexes. The 
assembly of multicomponent signaling complexes downstream of ligand-receptor interactions 
is an important step in kinase activation and transcriptional regulation. Complexes containing 
TANK, TRAF3 and TRIF or MAVS have been suggested to trigger TBK1 which in turn 
phosphorylate IRF3 (114;121). C-Src has previously been shown to induce synergistic AP-1 
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activation in a signaling complex with TRAF6 in response to IL-1 (235). Moreover, Akt/PKB 
was reported to be activated by TRANCE through a complex involving TRAF6 and c-Src 
(236). In the same study TRAF3 interacted with c-Src. but the molecular mechanisms or 
functional importance of the latter interaction was not addressed. TRAF3 has been described 
as a regulator of IFN production (237) and is reported to interact with several nonrelated 
kinases, as discussed above. We show that c-Src is recruited to IRF3 activating complexes 
downstream the cytoplamic receptor RIG-I. In a similar manner, c-Src may convey TLR3-
induced signals by interacting with TRAF3 and TRIF.
The exact function and phosphorylation target of c-Src in antiviral signaling pathways is, 
however, not assessed. C-Src could associate directly with TLR3 and RIG-I or through other 
signaling components, eg. TRIF, MAVS or TRAF3. The kinase domain of c-Src is 
responsible for its tyrosine kinase activity and plays an important role in substrate specificity. 
A possible interaction between c-Src and antiviral receptors and signaling components might 
be mediated by tyrosine phosphorylation. TLR3 contains several tyrosine-based sorting 
signals (YXXØ, Ø=hydrophobic) within its cytoplasmic domain, which normally target 
transmembrane proteins to the endosomal pathway (238). The amino acid sequence preferably 
phosphorylated by c-Src is EEEIYG/EEFD. However, this sequence is not found in human 
TLR3, TRIF, RIG-I, MAVS or TRAF3. It has recently been demostrated that Bruton`s 
tyrosine kinase (Btk) elicits tyrosine phosphorylation in TLR responses. The adaptor protein 
Mal is phosphorylated by Btk upon TLR2 and TLR4 signaling (198). Further, Btk is activated 
by and recruited to TLR8 and TLR9. Importantly, Btk-mediated tyrosine phosphorylation is 
required for NF-țB activation by TLR8 and TLR9 (203). Components of the TLR3 and RIG-I 
signaling pathways could undergo tyrosine phosphorylation by alternative/unidentified 
kinases, generating phosphorylated tyrosine residues that bind the SH2 domain of c-Src. 
Some proteins that bind to the SH2 domain of c-Src harbour the optimum binding structure 
YEEI. This binding structure is not present in human TLR3, TRIF, RIG-I, MAVS or TRAF3. 
However, not all proteins binding to the SH2 domain of c-Src possess such sequence. The 
platelet-derived growth factor (PDGF) and colony-stimulating factor (CSF)- I receptors that 
are phosphorylated at the sequences YIYV and YTFI, respectively, yet bind Src and Fyn 
through their SH2 domains (178;239;240). The SH3 domain of c-Src binds the common 
PXXP amino acid sequence of substrate proteins (241). TRIF and MAVS contain several such 
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proline-rich motifs that may mediate a possible interaction with c-Src. The cytoplasmic 
signaling protein TRAF6, which acts downstream of MyD88, interacts with c-Src and this 
interaction was reported to depend on a polyproline motif within TRAF6, as well as c-Src 
kinase activity (242). Taken together, c-Src may act as a positive effector of complex 
formation in TLR3- and RIG-I signaling at the level of TRIF/TRAF3 and MAVS/TRAF3, 
hence regulating downstream kinases, such as TBK1 and IKKİ, and subsequent activation of 
IRF3.
Alternatively, c-Src may elicit its function at the level of TBK1 and IKKİ. TBK1 is a 
serine/threonine kinase, but its activation mechanism is not known. It is possible that TBK1 
undergoes autophosphorylation and activates itself. Moreover, TBK1 might be activated 
through sequential mechanisms, e.g. autophosphorylation subsequent to tyrosine 
phosphorylation, which could involve c-Src kinase activity. In light of that, TBK1 harbours a 
motif containing a serine close to a tyrosine (SLY) within its activation loop. It has also been 
suggested that alternative kinases are implicated in IRF3 activation through other residues 
than those targeted by TBK1 (243;244). c-Src could mediate activation of such kinases, as 
shown for Akt activation in paper I. We demonstrated that treatment with dsRNA triggered 
activation of Akt, and that c-Src altered this activation. c-Src has previously been reported to 
directly phosphorylate Akt to control its activation (245). However, the role of c-Src in TLR-
induced Akt activation has not been described. A study by Sarkar et al. demonstrated that the 
PI3-kinase/Akt pathway is necessary for maximal phosphorylation and activation of IRF3 
downstream of TLR3, but does not involve TBK1 (201). This supports the hypothesis that 
activation of IRF3 may rely on additional kinases. Akt has also been implicated in antiviral 
signaling from other PRRs. Vesicular stomatitis virus (VSV) was recently reported to induce 
TLR4-dependent, MyD88-independent Akt activation (246). Moreover, Peters et al. showed 
that SV infection activates Akt. However, the latter study claimed that SV-induced IRF3 
activity is unaffected by impairment of Akt function, and that Akt rather regulates caspase-8-
mediated apoptosis upon SV infection. (247). Hence, regulation of IRF3 activity through the 
PI3-kinase/Akt pathway could be specific for TRIF responses and might not be implicated in 
RIG-I-mediated signaling.  
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Several publications illustrate the complexity of IRF3 regulatory mechanisms. TANK has 
been shown to undergo both phosphorylation and subsequent K63-linked ubiquitination 
(248). Also, additional components of innate antiviral signaling pathways are regulated by 
ubiquitination, e.g. RIG-I that is ubiquitinated by the E3 ligase TRIM25, a modification that is 
critical for type I IFN production. We and others (104;114) present a model of the assembly 
of antiviral signaling complexes in which TRAF3 is a central component. Still, it is not 
completely characterized how TRAF3 is activated and transmit signals to IRF3. TRAF3 was 
recently reported to become ubiquitinated in a K63-linked manner resulting in the recruitment 
of TBK1 (110). Similarly, the NF-țB pathway involves TRAF6-mediated K63-linked 
ubiquitination leading to activation of TAK1. Thus, signaling from TRAF interacting 
receptors is generally thought to involve K63-linked ubiquitination of target proteins in order 
to promote protein-protein interactions and activation of kinases in either the NF-țB pathway 
or the IRF3 pathway. In conclusion, TRAF3 might function as a platform recruiting kinases, 
e.g. c-Src, that elicits phosphorylation dependent post-translational modifications, such as 
ubiquitination.
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Figure 7: Schematic summary of paper II. C-Src tyrosine enhances RIG-I-mediated activation of IRF3 and 
induction of IRF3-regulated genes. C-Src associates with components of the RIG-I signaling pathway and 
specifically interacts with the RING domain of TRAF3. The present model proposes that c-Src functions in a 
multicomponent complex in both TLR3- and RIG-I-induced responses at the level of TRAF3. 
                                                                                                                                                                                              
 4.5 C-Src tyrosine kinase differentially regulates TLR-dependent gene expression 
Transcription of cytokines is regulated by a complex set of transcription factors and dynamic 
signaling networks. The IRF family consists of 9 members with distinct specificities 
depending on discrete regulatory mechanisms.  So far we have discussed that c-Src positively 
regulates IRF3 activity downstream of TLR3 and RIG-I antiviral signaling pathways. Further, 
it was of interest to explore if c-Src did affect the regulation of other IRF family members. In 
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paper III, we demonstrated that c-Src tyrosine kinase differentially regulates TLR-mediated 
gene expression. Consistent with what observed for poly IC- and SV-induced IRF3 activation 
in paper I and II, we found that CpG-induced activation of IRF3 was attenuated by chemical 
inhibition of c-Src. Interestingly chemical inhibition of c-Src had the opposite effect on IRF5 
activation in response to CpG. The effect on IRF5, however, could not be assessed in the 
content of TLR3 as we and others found that poly IC failed to activate IRF5 (249). These 
findings suggest that c-Src may exert a negative regulatory role in IRF5 activation. The effect 
of c-Src inhibition on IRF5 required prolonged CpG treatment, indicating that c-Src regulates 
a delayed phase of CpG-induced gene transcription. Similarly, chemical inhibition of c-Src 
augmented CpG-mediated gene induction of IL-6 after prolonged stimulation, whereas CpG-
triggered gene induction of IP10 was attenuated. IRF5 has been reported to regulate 
transcription of IL-6 in response to various ligands (101), and IRF3 has been suggested to be 
critical for TLR elicited synthesis of IP10 (87;250). We demonstrated that MEFs lacking 
expression of c-Src, Yes and Fyn (SYF) elicited enhanced IL6 induction from several TLR 
ligands, including LPS, R848, CpG and poly IC. On the other hand, IP10 transcription 
triggered by TLR ligands was abrogated in the same cell line. In general, TLRs are highly 
expressed in specialized immune cells, such as monocytes, macrophages and dendritic cells. 
Importantly, all TLRs are also expressed in the MEF cell line, and the MEFs are reported to 
respond to TLR ligand activation (251). Supporting the results from the MEF cell line, we 
found that chemical inhibition of c-Src enhanced the production of IL-6 and inhibited the 
production of IP10 in response to various TLR ligands. Collectively, we believe that c-Src 
enhances IRF3-dependent gene induction (IP10) and negatively regulates IRF5-dependent 
gene induction (IL6) in response to a range of PAMPs and downstream of both MyD88-
dependent and -independent signaling. 
 4.6 C-Src tyrosine kinase regulates TLR-elicited induction of ATF3, a negative 
regulator of TLR signaling 
A number of mechanisms have been described that downregulate cytokine signaling, thus 
preventing overaction of these immune effectors (252). Our results in paper III pointed 
towards a role for c-Src in inhibiting negative regulators of TLR signaling. Moreover, the 
effect of c-Src on IRF5 was observed after prolonged TLR stimulation. Signaling involved in 
the control of delayed TLR-responses may depend on induction of TLR-specific genes. IRF4 
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is known to negatively regulate IRF5 by competing for MyD88 (102). However, we could not 
observe any effect of TLR ligands or c-Src functional impairment on IRF4 mRNA levels. 
This indicates that the contribution of c-Src as a negative regulator of IRF5-dependent gene 
expression is not due to IRF4 induction. Still, we can not exclude that IRF4 may impact on 
IRF5 transcriptional control through protein-protein interactions. SOCS3 is reported to inhibit 
innate immune responses (252). In particular, SOCS3 overexpression inhibits NF-țB and IL-8 
activities, as well as IFN-ȕ expression during virus infection (253). Moreover, SOCS3 is 
reported to regulate secondary effects of TLR-mediated cytokine signaling, e.g. LPS-induced
macrophage activation through regulation of IL-1, TGF-ȕ, IL-10 and IL-6 (254). We found 
that TLR ligands were able to induce SOCS3 mRNA, and that the SOCS3 mRNA levels were 
extensively increased upon c-Src inhibition. Thus, enhanced transcription of IL-6 upon c-Src 
inhibition could not be explained by altered SOCS3 levels. The transcription factor ATF3 
differs from the rest of the ATF family by its ability to repress rather than activate 
transcription from promoters with ATF/CRE binding sites (172). Interestingly, ATF3 was 
recently identified as a negative regulator of TLR4 signaling. In particular, ATF3 was shown 
to inhibit IL-12-ȕ and IL-6 transcription (174;255). We found that ATF3 was rapidly induced 
in response to TLR ligands. Interestingly, CpG-induced ATF3 levels were elevated upon 
prolonged treatment. Given that ATF3 functions as a negative regulator in TLR responses, its 
high expression in response to prolonged stimulation may help the cell to tune down the 
response during late phases by inhibiting cytokine production. The elevated mRNA levels of 
ATF3 at delayed phases could also be explained by post-transcriptional regulation. Several 
studies have reported that the mRNA stability of cytokines and other protein transcripts is 
tightly regulated during inflammation (256;257). Nevertheless, impairment of c-Src by 
chemical inhibition and by using cells lacking c-Src expression abrogated induction of ATF3 
mRNA. Also, c-Src activity regulated intracellular ATF3 levels, indicating that c-Src activity 
is necessary for induction of ATF3. The ATF3 promoter contains a consensus TATA box and 
a number of transcription factor binding sites including the AP-1, ATF/CRE, NF-țB, E2F, 
and Myc/Max binding sites. Actually, c-Src has previously been reported to modulate AP-1 
activity triggered by IL-1 (235). Bioinformatics data showed that IL-6 and IL-12-ȕ promoters 
harbour ATF or CRE sites. Thus, it is likely that ATF3 binds to these promoters, and possibly 
represses the production of IL-6 and IL-12-ȕ upon TLR signaling. Moreover, binding of 
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ATF3 to specific promoters could be reduced by impaired c-Src function due to decreased 
ATF3 protein and consequently reduced ATF3 levels in the nucleus.  
It was previously reported that ATF3 binds to the IL-6 and IL-12-ȕ promoters upon LPS 
challenge (174). Still, the mechanisms behind ATF3-mediated repression of transcription are 
not fully understood. When it comes to LPS-triggered transcription, it was found that ATF3 
was recruited to the promoters with slower kinetics than the NF-țB subunit Rel. This is in 
accordance with a possible role in delayed phases of TLR responses. Moreover, it was 
demonstrated that LPS triggered association between ATF3 and the chromatin modifying 
enzyme histone deacetylase in the nucleus (174). Hence, the molecular mechanism for ATF3-
mediated repression of IL-6 transcription may be deacetylation of histones generating an 
inaccessible chromatin structure on the IL-6 promoter. In that regard, it was recently shown 
that chromatin modifications, such as histone methylations, acetylations and 
phosphorylations, differentially labelled TLR-elicited genes and might govern gene-specific 
rather than transcription factor dependent induction during distinct temporal phases (258-261) 
Also, it has been reported that NF-țB is recruited to promoters in either of two modes; fast 
recruitment to constitutive accessible promoters or slow recruitment to promoters that 
undergo stimuli-dependent modifications of chromatin structure (262). We believe that ATF3 
binding to promoters represents a mechanism for control of chromatin accessibility. Thus, c-
Src may play a role in chromatin-regulated transcription during late phases of TLR responses. 
Currently, we have not studied the mechanisms by which c-Src positively regulates ATF3 
transcription. It has been reported that stress-signals affect transcription of ATF3, probably 
via the JNK/SAPK-regulated pathways (263). We demonstrated that ATF3 induction in 
response to various TLR signals depends on c-Src. Also, several TLR ligands induce 
JNK/SAPK signaling. Therefore, ATF3 induction might be regulated through mechanisms 
common downstream of TLRs, involving c-Src tyrosine kinase. This also implies a possibly 
broad role of ATF3 in innate immune responses to pathogens. 
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Figure 8: Schematic summary of paper III. During early phases of TLR responses, c-Src tyrosine kinase 
enhances induction of the IRF3-regulated gene IP10. Moreover, TLR-triggered induction of the transcription 
factor ATF3 is positively regulated by c-Src. ATF3 in turn, represses induction of the IRF5-regulated gene IL-6. 
Hence, we propose that c-Src negatively regulates the induction of the IRF5-regulated gene IL6 during late 
phases of TLR responses by controlling intracellular ATF3 levels. 
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 5 CONCLUSIONS
In this study we demonstrate that c-Src tyrosine kinase is important for TLR3- and RIG-I-
dependent activation of IRF3 and induction of type I interferons. We provide insight into the 
subcellular site of interaction between TLR3, dsRNA and c-Src. We show that c-Src 
associates with components of antiviral signaling pathways, and we reveal the molecular 
explanation behind its interaction with the cytoplasmic adaptor TRAF3. Further, we 
demonstrate that c-Src differentially regulates TLR-induced gene expression through different 
IRF family members, and we assess the biological explanation behind its negative control of 
the IRF5-regulated cytokine IL-6. Taken together, we provide insight into the role of c-Src in 
innate immune responses, in the regulation of antiviral signaling and the complex control of 
TLR-triggered cytokine production. Our results imply that c-Src modulates antiviral 
responses to diverse viruses and may play a broader role in innate immune defence 
mechanisms. We propose that this study adds to the general understanding of innate immune 
mechanisms, which could be of importance for the development of vaccines and new 
treatments against infectious diseases and cancer.
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